Tracy M. Valorie

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

Samsara Vision, Inc. engages in the business of research, development, manufacturing, and marketing proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. It operates under the United States and Other geographical segments. The company was founded by Isaac Lipshitz, David Lifschitz, Yossi Gross, Boaz Lifschitz, and Eyal Lifschitz in 1997 and is headquartered in Far Hills, NJ.

Layerbio, Inc. develops bio erodible sustained-release technology for use in standard intraocular lens in cataract surgery. The private company is based in Lexington, MA. The company was founded in 2013 by Kenneth J. Mandell, Paula Hammond. Kenneth J. Mandell has been the CEO since 2013.

Sprout Pharmaceuticals, Inc. provides delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder. The company was founded by Cynthia E. Whitehead and Robert S. Whitehead on November 29, 2011 and is headquartered in Raleigh, NC.

PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.